Margolin KA - Search Results

1

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).

Lawson DH, Lee S, Zhao F, Tarhini AA, Margolin KA, Ernstoff MS, Atkins MB, Cohen GI, Whiteside TL, Butterfield LH, Kirkwood JM. Lawson DH, et al. Among authors: margolin ka. J Clin Oncol. 2015 Dec 1;33(34):4066-76. doi: 10.1200/JCO.2015.62.0500. Epub 2015 Sep 8. J Clin Oncol. 2015. PMID: 26351350 Free PMC article. Clinical Trial.

2

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.

Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, et al. Weiss GR, et al. Among authors: margolin ka. J Clin Oncol. 1992 Feb;10(2):275-81. doi: 10.1200/JCO.1992.10.2.275. J Clin Oncol. 1992. PMID: 1732429 Clinical Trial.

3

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, Sznol M, Dutcher JP, Aronson FR, Doroshow JH, et al. Parkinson DR, et al. Among authors: margolin ka. J Clin Oncol. 1990 Oct;8(10):1650-6. doi: 10.1200/JCO.1990.8.10.1650. J Clin Oncol. 1990. PMID: 2213101 Clinical Trial.

4

Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.

Bar MH, Sznol M, Atkins MB, Ciobanu N, Micetich KC, Boldt DH, Margolin KA, Aronson FR, Rayner AA, Hawkins MJ, et al. Bar MH, et al. Among authors: margolin ka. J Clin Oncol. 1990 Jul;8(7):1138-47. doi: 10.1200/JCO.1990.8.7.1138. J Clin Oncol. 1990. PMID: 2358835

5

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Jaffe HS, Roper M, et al. Margolin KA, et al. J Clin Oncol. 1989 Apr;7(4):486-98. doi: 10.1200/JCO.1989.7.4.486. J Clin Oncol. 1989. PMID: 2647914 Clinical Trial.

6

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.

Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI, et al. Atkins MB, et al. Among authors: margolin ka. J Clin Oncol. 1994 Aug;12(8):1553-60. doi: 10.1200/JCO.1994.12.8.1553. J Clin Oncol. 1994. PMID: 8040667 Clinical Trial.

7

A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma.

Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Margolin KA, Rayner AA, Sznol M, Parkinson DR, Paietta E, et al. Hawkins MJ, et al. Among authors: margolin ka. J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):74-8. doi: 10.1097/00002371-199401000-00010. J Immunother Emphasis Tumor Immunol. 1994. PMID: 8110733 Clinical Trial.

8

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.

Margolin K, Aronson FR, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland M, Doroshow JH, Ernest ML, Mier JW, et al. Margolin K, et al. J Immunother Emphasis Tumor Immunol. 1994 Feb;15(2):147-53. doi: 10.1097/00002371-199402000-00009. J Immunother Emphasis Tumor Immunol. 1994. PMID: 8136948 Clinical Trial.

9

Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.

Sosman JA, Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, O'Boyle K, Fisher RI, Boldt DH, Doroshow J, et al. Sosman JA, et al. Among authors: margolin ka. J Clin Oncol. 1993 Aug;11(8):1496-505. doi: 10.1200/JCO.1993.11.8.1496. J Clin Oncol. 1993. PMID: 8336188 Clinical Trial.

10

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.

Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR, et al. Sparano JA, et al. J Clin Oncol. 1993 Oct;11(10):1969-77. doi: 10.1200/JCO.1993.11.10.1969. J Clin Oncol. 1993. PMID: 8410122 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

293 results

Search Page